Description

IQVIA: AI Adoption By Top Pharma Creates A New Engagement Lever!

IQVIA’s first quarter 2026 financial results reflect growth in both top-line revenue and earnings per share, surpassing the high end of the company’s guidance. Total revenue reached $4.151 billion, representing an 8.4% increase year-over-year on a reported basis and 6.0% at constant currency, with Commercial Solutions growing 11.6% and R&D Solutions up 6.2%. Adjusted diluted earnings per share rose 7.4% to $2.90. Adjusted EBITDA increased by 5.5% to $932 million, while net income on a GAAP basis was $274 million, or $1.61 per diluted share. Free cash flow improved 15% to $491 million, representing 100% of adjusted net income. The company repurchased $552 million of shares during the quarter. The company attributed solid organic revenue growth acceleration across its portfolio, with Commercial Solutions organic growth doubling and R&D Solutions tripling year-over-year.